Small molecules that can target human cancers have been highly sought to increase the anticancer efficacy, the present work describes the design and synthesis of novel series of five quinuclidinone derivatives (2a-2e). Their anticancer activities were investigated against breast cancer cells MCF-7, MDA-MB-231 breast cancer cells harboring mutant p53 and normal breast counterpart MCF-12a. Derivative 2e reduced proliferation of MCF-7 and MCF-12a while it has no effect on MDA-MB-231. Derivative 2e induced apoptosis in MCF-7 cells which is further confirmed by TUNEL assay and it reduced the percentage of cell in G2/M phase as confirmed by increased expression of cyclin B and reduced expression of cyclin D1. Derivative 2e reduced expression levels of Mdm2, Akt and ERK1/2 by and increased expression level of p53. Moreover, the apoptosis induction by 2e was also inhibited by PFT-α as evidenced by non-significant induction of apoptosis after treatment of MCF-7 cells with both derivative 2e and PFT-α. In addition, docking study reveals that derivative 2e has a binding pattern close to the pattern observed in the structure of the lead fragment 5,6-dimethoxy-2-methylbenzothiazole bound to T-p53C-Y220C. The above findings demonstrate that derivative 2e induces apoptosis in MCF-7 cells via targeting p53 which merits further development.
Introduction
Cancer today accounts for more deaths worldwide than tuberculosis, HIV, and malaria combined. Breast cancer is the most common cancer among women. It will afflict an estimated 9.1 million women in poorer countries over the next decade. Of the 5 million women expected to die from breast cancer in the next decade, 70 percent will live in lowand middle-income countries 1 .
Breast cancer is a heterogeneous disease and different breast cancer subtypes can be identified based on gene expression profiling. Current breast cancer therapies, based on Selective Estrogen Receptor Modulators (SERMs), such as tamoxifen or aromatase inhibitors, can be unsuccessful due to intrinsic or acquired resistance to these therapies 2 .
Consequently, discovery and development of new class of anticancer drugs are urgently needed to combat the growing threat of high mortality rate.
Quinuclidinones belongs to the group of bicyclic bridgehead lactams and are highly twisted.
This twisted nature decreases the delocalization effect, increasing the basicity of the nitrogen so that it often behaves more like an amine than as a typical planar amide. This might increase selectivity and affinity of a pharmacophore element towards different receptor binding sites 3 . Literature survey revealed that The molecule 3-quinuclidinone is an attractive candidate in medicinal chemistry as it constitute the building block of wide range of many pharmacologically active compounds having anticancer effect 4 , antihistaminebronchodilating activity 5 , nicotinic receptors inhibitory activity 6 , anti Alzheimer's effect 7 . In addition, it has been reported that quinuclidine moiety constitute the basic skeleton for many synthetic pharmacologically active existing drugs for example; palonosetron and azasetron as 5-HT3 receptor blockers 8 , solifenacin and cevimeline as muscarinic receptor antagonists 9 apoptosis has emphasized its role as a transcription factor 14 . The p53 protein been thought to be the molecular target of Pifithrin-alpha (PFT) which has been widely used as a ubiquitous and reversible inhibitor of p53 and p53 mediated apoptosis 15 . The pharmacological rescue of inactive p53 may therefore represent an attractive therapeutic strategy. Pifithrin-alpha (PFT)
is an inhibitor of p53 and is considered to be useful for therapeutic suppression to protect against various genotoxic agents
16
. Several reports have shown that Pifithrin-alpha (PFT) blocks the p53-mediated activation of autophagy caused by stress-inducing agents 17. PFT has been validated as a useful p53 inhibitor for the elucidation of p53 functions in experimental studies.The pharmacological salvage of inactive p53 may represent an attractive therapeutic tool. Pifithrin-alpha (PFT) is an inhibitor of p53 and is considered to be useful for therapeutic suppression in order to reduce cancer treatment side effects and to protect against various genotoxic agents
. Several reports have shown that PFT blocks the p53-mediated apoptotic effect caused by chemical agents 17 . In summary, PFT has been validated as a useful p53 inhibitor for investigating p53 functions in experimental studies.
In view of the above mentioned results and as a continuation of our research on Quinuclidinones in an attempt to identify new lead compounds that might be of value for future development as new class of anticancer agents, a series of novel quinuclidinone based amines (2a-2e) were synthesized. The structures of title compounds were well supported by spectroscopic data and elemental analysis. The target compounds comprise some pharmacophoric elements which influence the biological activity of the molecules, such as the aryl ring as hydrophobic binding site, the nitrogen of the secondary amine as electron donor, additional NH group as hydrogen bonding domain. To understand the mechanism of action and the effects on cancer biology, we evaluated the effect of the most promising compounds on cell cycle, apoptosis and the tumor suppressor p53. A molecular docking study was also performed for the most active compounds in a trial to investigate the possible mode of action of these compounds.
Results and discussion

Chemistry
The synthetic strategies to obtain the target compounds are depicted in Scheme 1. The key starting material 2-methylenequinuclidine-3-one hydrochloride 1 was refluxed with phenyl and 4-nitrophenyl hydrazine in ethanol in the presence of sodium bicarbonate to yield the corresponding N-[ (3-oxo-quinuclidin-2yl) We treated MDA-MB-231 with derivative 2e in order to determine if this derivative is working via p53 dependent or p53 independent mechanism. Our data revealed that our 6 derivatives 2e did not affects the cell viability in MDA-MB-231 cells and it did not induce any significant increase in apoptosis under the same conditions ( Figure 2F ,G).
Quinuclidinone derivatives 2e modulates G2/M checkpoint
MCF-7 cells were treated with 4 μM of 2e and harvested after 24 h and showed a significant decrease in the percent of G2/M cells (10%) compared to control group (30%) ( Figure 3A ). The abrogation of G2/M checkpoint was confirmed by the increased expression levels of cyclin B (2-fold increase) and reduction of cyclin D levels (4-fold decrease) ( Figure 3B ).
Quinuclidinone derivatives 2e modifies apoptotic signals and increase p53 expression
Apoptosis occurs due to an imbalance between pro and anti-apoptotic proteins.
Derivative 2e reduced expression levels of Mdm2, Akt and ERK1/2 by (4, 3 and 2 fold respectively) and increased expression level of p53 (2.5-fold) ( Figure 4A ). We next examined the role of p53 transcription by using a p53 transcriptional inhibitor, PFT-α, a specific inhibitor of p53 transcriptional targets. As shown in Figure3A, PFT-α inhibited the up-regulation of p53 and it suppressed activation of p53 targets Mdm2, Akt and Erk1/2 ( Figure 4B ). Moreover, the apoptosis induction by 2e was also inhibited by PFT-α as evidenced by non-significant induction of apoptosis after treatment of MCF-7 cells with both 2e and PFT-α ( Figure 4C ).
From the above study it was appeared that compound 2e is the most active deivative. It induced apoptosis in MCF-7 and increasesd expression of tumor suppressor p53. The increased activity of compound 2e is related to the pharmacophoric elements which influence its biological activity such as NH group of benzimidazole ring which forms an additional hydrogen bonding domain. In addition, benzimidazole ring displayed hydrophobic interactions with the hydrophobic binding site in the receptor.
Molecular Modeling
The docking study was carried out using the enzyme parameters obtained from the crystallographic structure of T-p53C-Y220C (a stable variant of p53 core domain with the Y220C mutation) bound to the lead fragment 5,6-dimethoxy-2-methylbenzothiazole (PDB ID: 2X0W) 19 . The docking simulation for the ligand was carried out using molecular operating environment (MOE) software supplied by the Chemical
Computing Group, Inc., Montréal Canada 20 .
The structure of lead fragment 5,6-dimethoxy-2-methylbenzothiazole bound to T-p53C-Y220C showed that the molecule sits in an upright position within the mutationinduced cavity (Figure5). The thiazole nitrogen is within hydrogen-bonding distance of the hydroxyl group of Thr150. The methoxy moieties of the molecule sit at the bottom of the cavity in close proximity to Cys220. Figure 6 shows the binding mode of compound 2e docked and minimized in the mutation induced cavity of T-p53C-Y220C. In this case, hydrogen bond is observed between the nitrogen of benzimidazole and the hydroxyl group of Thr150. Hydrogen bond is also observed between NH group and oxygen of Thr150.
In addition, compound 2e displayed hydrophobic interactions with the same amino acids Val147, Pro151, Cys 220 and Glu221 bound to the lead fragment.
The docking study shows that compound 2e has a binding pattern which is close to the pattern observed in the structure of the lead fragment 5,6-dimethoxy-2-methylbenzothiazole bound to T-p53C-Y220C. Compound 2e forms hydrogen bonds with the same residue (Thr150) as that observed in the structure of the lead fragment with T-p53C-Y220C. This may account for increased activity recorded for compound 2e.
Conclusion
Apoptosis occurs due to an imbalance between pro and anti-apoptotic proteins. supplemented with 10% Fetal Bovine Serum, 100 Units/ml penicillin and 100 μg/ml streptomycin at 37 o C in a 5% CO2 atmosphere (Gibco, California, USA). MCF-12a cells were maintained in DMEM/F-12 media (Gibco, California, USA) supplemented with 10% FBS, 100 Units/mL penicillin, 100 μg/mL streptomycin, insulin (1.2 g/L), transferrin (0.001 mg/mL), EGF (20ng/μL) and hydrocortisone (500 ng/mL) at 37°C in a 5% CO 2 atmosphere. The synthesized compounds were prepared in 10μM concentration and dissolved in suitable media.PFTα (1-(4-methylphenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)benzothiazolyl)ethanone hydrobromide) was purchased from
Cayman Chemical Company (Ann Arbor, Michigan USA).
Methyl tetrazolium (MTT) bromide mitochondrial activity assay
Cell viability was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as described previously(ATCC, Manassas, VA USA). Briefly, 4000-5000 cells/well in 100 µL of medium were seeded into 96-well plates. After 24 h incubation at 37 °C, the culture media were removed and replaced with fresh media containing the test compounds (100 μM). The cells were incubated for another 24 h then, 10 µL of 5 mg/ mL MTT reagent was added to each well and incubated for 4 h at 37 °C. After incubation, 100 µL of detergent reagent was added to each well to dissolve the formazan crystals. The absorbance was determined at 570 nmusing Spectra Max Plus. Each assay was performed in triplicate and the experiment was repeated three times and standard deviation was determined. To determine the IC 50 of compound 2e, the assay was conducted using different concentrations of compound 2e and the average 50% inhibitory concentration (IC 50 ) was determined from the dose response curve.
Enzyme linked immunosorbent apoptosis assay
Cells were seeded at a density of 2 X 10 4 / well in a 96-well plate and incubated for 24
hours. Media were changed to media containing compound 2e (4 μM). Cells were then incubated for 24 hours. An ELISA assay was performed using Cell Death Detection The coordinates from the X-ray crystal structure of T-p53C-Y220C used in this simulation were obtained from the Protein Data Bank (PDB ID: 2X0W), where the active site is bound to 5,6-dimethoxy-2-methylbenzothiazole. The ligand molecule was constructed using the builder module and were energy minimized. The active site of Tp53C-Y220C was generated using the MOE-Alpha Site Finder, and then the ligand was docked within this active site using the MOE Dock. The lowest energy conformation 13 was selected and the ligand interactions (hydrogen bonding and hydrophobic interaction) with T-p53C-Y220C were determined.
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